Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O5S |
Molecular Weight | 365.404 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O
InChI
InChIKey=LSQZJLSUYDQPKJ-NJBDSQKTSA-N
InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
Molecular Formula | C16H19N3O5S |
Molecular Weight | 365.404 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Amoxicillin is one of the widely prescribed antibacterial agents, which was discovered by scientists at Beecham Research Laboratories in 1972. In the US GlaxoSmithKline markets it under the original brand name Amoxil. It is the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections it is taken by mouth. Amoxicillin inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. This results in a formation of defective cell wall and a cell death. Common side effects include nausea and rash. It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea. It should not be used in those who are allergic to penicillin.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12461003 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date1980 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date1980 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date1980 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date1980 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date1980 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Disc. AE: Pharyngolaryngeal pain... Other AEs: Nausea, Pharyngotonsillitis... AEs leading to discontinuation/dose reduction: Pharyngolaryngeal pain (severe, 0.6%) Other AEs:Nausea (1.5%) Sources: Pharyngotonsillitis (0.9%) Vulvovaginal candidiasis (0.9%) Headache (0.7%) Diarrhea (0.5%) Abdominal pain (0.5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 0.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Diarrhea | 0.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Headache | 0.7% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Pharyngotonsillitis | 0.9% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Vulvovaginal candidiasis | 0.9% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Nausea | 1.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Pharyngolaryngeal pain | severe, 0.6% Disc. AE |
775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 50 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
unlikely [Ki 11000 uM] | ||||
unlikely [Ki 66200 uM] | ||||
unlikely [Ki 733 uM] | ||||
yes [IC50 0.83 uM] | ||||
yes [IC50 28.9 uM] | ||||
yes [IC50 36.2 uM] | ||||
yes [IC50 56.6 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes [Km 1040 uM] | ||||
yes [Km 161.4 uM] | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. | 2001 |
|
Amoxicillin plus metronidazole in the treatment of adult periodontitis patients. A double-blind placebo-controlled study. | 2001 Apr |
|
A prospective observational study of 5-, 7-, and 10-day antibiotic treatment for acute otitis media. | 2001 Apr |
|
Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics. | 2001 Apr |
|
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. | 2001 Apr |
|
Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. | 2001 Apr |
|
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. | 2001 Apr |
|
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | 2001 Apr 1 |
|
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. | 2001 Apr 6 |
|
[Eradication therapy of Helicobacter pylori infection]. | 2001 Feb |
|
[The history of Helicobacter pylori]. | 2001 Feb |
|
Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate. | 2001 Feb |
|
Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet. | 2001 Feb |
|
Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic. | 2001 Feb |
|
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. | 2001 Feb |
|
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication. | 2001 Feb |
|
Managing pneumonia in general practice. | 2001 Feb |
|
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment]. | 2001 Feb |
|
[Usefulness of new triple therapy containing PPI]. | 2001 Feb |
|
[Selection of antibiotics and planning of eradication for H. pylori infection]. | 2001 Feb |
|
Free radical production by antibiotic-killed bacteria in the guinea pig middle ear. | 2001 Feb |
|
Topical antibiotic prophylaxis for bacteremia after dental extractions. | 2001 Feb |
|
Clostridium difficile--Associated diarrhea: A review. | 2001 Feb 26 |
|
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?]. | 2001 Jan |
|
Antibiotic susceptibilities of Helicobacter pylori. | 2001 Jan |
|
[Pneumococcal antibiotic resistance. Results from 21 regional registries for 1999]. | 2001 Jan |
|
[Pneumococcal antibiotic resistance in 1999. Results from 19 registries for 1999]. | 2001 Jan |
|
[Pneumococcal antibiotic resistance. Data from 6 regional registries for 1999]. | 2001 Jan |
|
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. | 2001 Jan |
|
[Prevention of endocarditis within the scope of ENT interventions. Current recommendations]. | 2001 Jan |
|
[Dilated cardiomyopathy and panuveitis as presenting symptoms of Lyme disease. General review of one case]. | 2001 Jan |
|
High amoxycillin resistance in Helicobacter pylori isolated from gastritis and peptic ulcer patients in western Nigeria. | 2001 Jan |
|
Necrotizing meningoencephalitis associated with cortical hippocampal hamartia in a Pekingese dog. | 2001 Jan |
|
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age]. | 2001 Jan-Feb |
|
Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases? | 2001 Jan-Feb |
|
[A prospective study on erysipelas and infectious cellulitis: how are they dealt within hospital?]. | 2001 Mar |
|
Peptic ulcer occurrence in follow-up of chronic gastritis in patients with treated and not eradicated CagA-positive Helicobacter pylori infection. | 2001 Mar |
|
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. | 2001 Mar |
|
Lacrimal gland ductal cyst abscess. | 2001 Mar |
|
Screening method for identification of beta-lactams in bovine urine by use of liquid chromatography and a microbial inhibition test. | 2001 Mar |
|
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. | 2001 Mar |
|
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication. | 2001 Mar |
|
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 Mar |
|
Evaluation of the clinical microbiology profile of moxifloxacin. | 2001 Mar 15 |
|
Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. | 2001 Mar 31 |
|
Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. | 2001 Mar 31 |
|
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. | 2001 May |
|
Simultaneous determination of amoxycillin and clavulanic acid in pharmaceutical dosage forms by LC with amperometric detection. | 2001 May |
|
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
|
Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species. | 2001 May-Jun |
Sample Use Guides
In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Treatment of gonorrhea is 3 grams as a single oral dose. The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:01:36 GMT 2025
by
admin
on
Mon Mar 31 18:01:36 GMT 2025
|
Record UNII |
9EM05410Q9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175497
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
||
|
WHO-ATC |
J01CA04
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01060
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
26787-78-0
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
277174
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
DTXSID3037044
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL1082
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
9EM05410Q9
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
9EM05410Q9
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
2676
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
3230
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
3204
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
SUB05481MIG
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
C87367
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
33613
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
m1844
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
1297882
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000091596
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY | |||
|
248-003-8
Created by
admin on Mon Mar 31 18:01:36 GMT 2025 , Edited by admin on Mon Mar 31 18:01:36 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Cmax | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION PHARMACOKINETIC PHARMACOKINETIC |